FinVector Oy Revenue and Competitors
Estimated Revenue & Valuation
- FinVector Oy's estimated annual revenue is currently $35.6M per year.
- FinVector Oy's estimated revenue per employee is $201,000
Employee Data
- FinVector Oy has 177 Employees.
- FinVector Oy grew their employee count by 29% last year.
FinVector Oy's People
Name | Title | Email/Phone |
---|---|---|
1 | Responsible Director, QP | Reveal Email/Phone |
2 | HR Director | Reveal Email/Phone |
3 | Director MSAT | Reveal Email/Phone |
4 | Manufacturing Director | Reveal Email/Phone |
5 | Supply, Logistic and Procurement Director | Reveal Email/Phone |
6 | Finance Director | Reveal Email/Phone |
7 | Managing Director | Reveal Email/Phone |
8 | Operations Director | Reveal Email/Phone |
9 | Senior MSAT manager | Reveal Email/Phone |
10 | Team Lead, Downstream/ Project manager | Reveal Email/Phone |
FinVector Oy Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $16.1M | 80 | 7% | N/A | N/A |
#2 | $35.6M | 177 | 29% | N/A | N/A |
#3 | $27.9M | 139 | 6% | N/A | N/A |
#4 | $35.8M | 178 | 5% | N/A | N/A |
#5 | $10.5M | 52 | 30% | N/A | N/A |
What Is FinVector Oy?
FinVector is the world leader in the research and development of gene and cell therapies. Our state-of-the-art facilities, highly experienced scientific team and commitment to work closely with clients every step of the way, have helped us to build an excellent reputation in the gene therapy market. In addition to our own products, we operate as contract manufacturing organisation to clients' products and help them in their process development. We offer services across a wide range of viral-based product types, including Adenoviral, AAV, and Lentiviral-based vectors. From our cutting-edge fully-licensed GMP manufacturing facility in Finland, we have built an extensive pipeline of gene therapy products and technologies for our clients. Our mission is to improve and extend people's lives by finding solutions in advanced medicines. Moreover, we want to be a company that people aspire to work for. FinVector is based in Kuopio, Finland. We currently employ over 140 employees.
keywords:N/AN/A
Total Funding
177
Number of Employees
$35.6M
Revenue (est)
29%
Employee Growth %
N/A
Valuation
N/A
Accelerator
FinVector Oy News
Cobra Biologics Ltd. FinVector Oy; FUJIFILM Diosynth Biotechnologies; Genelux Corporation; Kaneka Eurogentec S.A.; Lonza Group AG; MaxCyte, Inc.
Cobra Biologics Ltd. FinVector Oy; FUJIFILM Diosynth Biotechnologies; Genelux Corporation; Kaneka Eurogentec S.A.; Lonza Group AG; MaxCyte, Inc.
Cognate BioServices Inc. · F. · FinVector Oy · FUJIFILM Holdings Corporation · Kaneka Eurogentec S.A. (Kaneka Corporation) · Lonza Group AG · Merck...
... leading ATMP manufacturer FinVector Oy and gene therapy developer FKD Therapies Oy, located in the same research campus in Kuopio.
Säätiö omistaa myös Kuopiossa geeniterapialääkkeitä kehittävän FinVector Oy:n, joka tunnettiin aiemmin nimellä Ark Therapeutics.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $69.1M | 299 | 6% | N/A |
#2 | $74.4M | 370 | 28% | N/A |
#3 | $110M | 489 | 4% | N/A |
#4 | N/A | 653 | 45% | N/A |
#5 | $204.6M | 1008 | 10% | N/A |